BIO 300 for Non-Small Cell Lung Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
The purpose of this study to find out whether giving BIO 300 in combination with thoracic radiation therapy is effective in preventing pneumonitis in people with non-small cell lung cancer (NSCLC) and interstitial lung disease (ILD).
Who Is on the Research Team?
Narek Shaverdian, MD
Principal Investigator
Memorial Sloan Kettering Cancer Center
Are You a Good Fit for This Trial?
This trial is for adults over 18 with Stage I-II non-small cell lung cancer (NSCLC) and interstitial lung disease (ILD). Participants need an ECOG performance status of 0-3, can give informed consent, and women must be post-menopausal or surgically sterile. A confirmed diagnosis of NSCLC is recommended but not mandatory if biopsy risks are too high.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive BIO 300 in combination with thoracic radiation therapy
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- BIO 300
Trial Overview
The study tests BIO 300 combined with thoracic radiation therapy to see if it prevents pneumonitis in patients with NSCLC who also have ILD. The effectiveness of this combination treatment will be evaluated against the risk of developing pneumonitis.
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
Participants with Non-Small Cell Lung Cancer/NCSLC and Interstitial Lung Disease/ILD
Find a Clinic Near You
Who Is Running the Clinical Trial?
Memorial Sloan Kettering Cancer Center
Lead Sponsor
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.